Abstract
Simple SummaryA decision support tool was developed to select head and neck cancer patients for proton therapy. The tool uses delineation data to predict expected toxicity risk reduction with proton therapy and can be used before a treatment plan is created. The positive predictive value of the tool is >90%. This tool significantly reduces delays in commencing treatment and avoid redundant photon vs. proton treatment plan comparison.Selection of head and neck cancer (HNC) patients for proton therapy (PT) using plan comparison (VMAT vs. IMPT) for each patient is labor-intensive. Our aim was to develop a decision support tool to identify patients with high probability to qualify for PT, at a very early stage (immediately after delineation) to avoid delay in treatment initiation. A total of 151 HNC patients were included, of which 106 (70%) patients qualified for PT. Linear regression models for individual OARs were created to predict the Dmean to the OARs for VMAT and IMPT plans. The predictors were OAR volume percentages overlapping with target volumes. Then, actual and predicted plan comparison decisions were compared. Actual and predicted OAR Dmean (VMAT R2 = 0.953, IMPT R2 = 0.975) and NTCP values (VMAT R2 = 0.986, IMPT R2 = 0.992) were highly correlated. The sensitivity, specificity, PPV and NPV of the decision support tool were 64%, 87%, 92% and 51%, respectively. The expected toxicity reduction with IMPT can be predicted using only the delineation data. The probability of qualifying for PT is >90% when the tool indicates a positive outcome for PT. This tool will contribute significantly to a more effective selection of HNC patients for PT at a much earlier stage, reducing treatment delay.
Highlights
There is a remarkable increase in the number of head and neck cancer (HNC) patients treated with proton therapy (PT) worldwide [1,2,3]
When these three proposed post-hoc adjustments were applied to the predicted Dmean values for salivary glands, the performance of the decision support tool for laryngeal cancer patients changed as follows: (1) when predicted IMPT Dmean was rescaled by 0.85, sensitivity increased from 25% to 63%, while specificity decreased from 100% to 50%, (2) when the lower bounds of the 95% CI of the coefficients were used to predict IMPT Dmean, sensitivity was 57%, and specificity was 57% and (3) when predicted IMPT Dmean values were decreased by 1 SD of the residuals (3.1 Gy, see Figure 4), sensitivity was 81%, and specificity was 50%
We developed a decision support tool to select patients for PT that can be used before any treatment plan is created
Summary
There is a remarkable increase in the number of head and neck cancer (HNC) patients treated with proton therapy (PT) worldwide [1,2,3]. When using multiple NTCP-models, a ∆NTCP profile can be created that can be considered as a biomarker for the expected benefit of protons compared to photons This called model-based selection has been used in the Netherlands since 2018 to select HNC patients for PT [9,11,12,13]. Centers that do not have a PT facility may refrain from consulting a PT center to check the suitability of a patient to be treated with PT, as this procedure may delay the initiation of treatment They need to create a VMAT plan first, send it to a PT center combined with other patient data and have to wait for an IMPT plan to be created and the results of a plan comparison being send back. It might result in treatment delays, especially for patients for whom a plan comparison result shows limited benefit from PT, in addition to the fee which may be asked by the PT center for the comparison that may not be covered by insurance companies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
